Boiron Past Earnings Performance

Past criteria checks 1/6

Boiron has been growing earnings at an average annual rate of 1.8%, while the Pharmaceuticals industry saw earnings declining at 5.2% annually. Revenues have been declining at an average rate of 2.5% per year. Boiron's return on equity is 6%, and it has net margins of 4.9%.

Key information

1.8%

Earnings growth rate

2.0%

EPS growth rate

Pharmaceuticals Industry Growth14.1%
Revenue growth rate-2.5%
Return on equity6.0%
Net Margin4.9%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Boiron makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0DTF Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24482243076
31 Mar 24487303076
31 Dec 23493363076
30 Sep 23505423126
30 Jun 23517483176
31 Mar 23526463146
31 Dec 22534453106
30 Sep 22528482985
30 Jun 22522512864
31 Mar 22489402814
31 Dec 21455292773
30 Sep 21453232863
30 Jun 21450182963
31 Mar 21482223043
31 Dec 20514263124
30 Sep 20534333183
30 Jun 20554403243
31 Mar 20556403343
31 Dec 19557413443
30 Sep 19569383513
30 Jun 19580353584
31 Mar 19592463604
31 Dec 18604573634
30 Sep 18609663604
30 Jun 18613753574
31 Mar 18615773594
31 Dec 17618783604
30 Sep 17616773614
30 Jun 17615763624
31 Mar 17615773594
31 Dec 16614783564
30 Sep 16616783574
30 Jun 16617793584
31 Mar 16612763564
31 Dec 15608743544
30 Sep 15616833524
30 Jun 15624913494
31 Mar 15617903485
31 Dec 14610893465
30 Sep 14607833466
30 Jun 14604763456
31 Mar 14611793456
31 Dec 13618823456

Quality Earnings: 0DTF has a large one-off loss of €8.0M impacting its last 12 months of financial results to 30th June, 2024.

Growing Profit Margin: 0DTF's current net profit margins (4.9%) are lower than last year (9.2%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0DTF's earnings have grown by 1.8% per year over the past 5 years.

Accelerating Growth: 0DTF's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 0DTF had negative earnings growth (-50.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9.5%).


Return on Equity

High ROE: 0DTF's Return on Equity (6%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 20:46
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Boiron SA is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Stéphan DubosqArkeon Finance
Guillaume CuvillierGilbert Dupont
Stephanie LefebvreGilbert Dupont